IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today joins with World
Ovarian Cancer Coalition and Ovarian
Cancer Canada in recognizing World
Ovarian Cancer Day (WOCD). This initiative aims to raise awareness
of, and bring hope to, the global challenges faced by women living with
a diagnosis of ovarian cancer.
“Ovarian cancer remains one of the most underserved, difficult-to-treat
forms of the disease,” said Frederic
Ors, Chief Executive Officer at IMV Inc. “IMV is committed to
developing an immunotherapy approach with the potential to make
meaningful difference in the lives of the women with ovarian cancer. We
are honored to support the World Ovarian Cancer Coalition and Ovarian
Cancer Canada, to be a part of the solution as we advance multiple
clinical studies of our product candidates in ovarian cancer, and to
amplify the patients’ voices and continue to drive awareness of this
urgent medical need.”
Over 150 ovarian cancer patient organizations from around the world work
together, year-round, as partners of the World Ovarian Cancer Coalition.
Each year on May 8th for WOCD, they come together to raise awareness of
ovarian cancer and the need for global action to tackle this disease for
every woman, no matter where she lives.
Elisabeth
Baugh, Chair of the World Ovarian Cancer Coalition, commented, “Our ‘Every
Woman Study,’ which surveyed more than 1500 women, found that
two-thirds of women who had been diagnosed with ovarian cancer had
either not heard of it or knew nothing about the disease prior to their
diagnosis. This is why it is crucial that we come together each year on
World Ovarian Cancer Day to raise awareness and speak with one voice in
our fight against this disease. I am proud to be part of a global
community that speaks out so loudly and passionately. I’m also
enormously grateful for the continued support of our partners.”
To demonstrate support for WOCD, IMV employees will wear teal – the
signature color of ovarian cancer awareness – and participate in a
social media campaign to spread awareness about ovarian cancer. Those
interested can join IMV, and other organizations around the world, today
in support of WOCD. Connect at https://ovariancancerday.org/get-involved/
About World Ovarian Cancer Coalition
The World Ovarian Cancer Coalition (WOCC) is a not-for-profit
organization, established in 2016, working across the globe to reduce
the impact ovarian cancer has on the lives of women and their loved
ones. The creation of the World Ovarian Cancer Coalition is a logical
and powerful next step that builds on the significant impact of the
annual flagship ovarian cancer awareness campaign – World Ovarian Cancer
Day. Our mission is to ensure the best possible chance of survival, and
the best quality of life for every woman with ovarian cancer – wherever
she lives.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious diseases. IMV
is pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T
cell-activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently assessing DPX-Survivac as a
monotherapy in advanced ovarian cancer, as well as a combination therapy
in multiple clinical studies with Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. In the press
release, such forward-looking statements include, but are not limited
to, statements regarding the FDA potentially granting accelerated
regulatory approval of DPX-Survivac. However, they should not be
regarded as a representation that any of the plans will be achieved.
Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials and the
receipt and timely receipt of all regulatory approvals. IMV Inc. assumes
no responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks and
uncertainties include, but are not limited to, our ability to access
capital, the successful and timely completion of clinical trials, the
receipt of all regulatory approvals and other risks detailed from time
to time in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking statements
and are encouraged to read IMV’s continuous disclosure documents,
including its current annual information form, as well as its audited
annual consolidated financial statements which are available on SEDAR at www.sedar.com and
on EDGAR at www.sec.gov/edgar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005176/en/
Copyright Business Wire 2019